Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 9424

1.

Early life adversity diminishes the cortisol response to opioid blockade in women: Studies from the Family Health Patterns project.

Lovallo WR, Acheson A, Vincent AS, Sorocco KH, Cohoon AJ.

PLoS One. 2018 Oct 12;13(10):e0205723. doi: 10.1371/journal.pone.0205723. eCollection 2018.

2.

Commentary: The opioid overdose epidemic: Evidence-based interventions.

Barglow P.

Am J Addict. 2018 Oct 12. doi: 10.1111/ajad.12823. [Epub ahead of print]

PMID:
30311993
3.

Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder.

Carroll KM, Nich C, Frankforter TL, Yip SW, Kiluk BD, DeVito EE, Sofuoglu M.

Drug Alcohol Depend. 2018 Oct 4;192:264-270. doi: 10.1016/j.drugalcdep.2018.08.019. [Epub ahead of print]

PMID:
30300800
5.

Extended-release morphine sulfate and naltrexone hydrochloride (EMBEDA®): naltrexone-associated withdrawal and abuse-related effects in patients with chronic pain and recreational opioid users.

Setnik B, Sommerville KW, Pixton GC, Webster L.

Curr Med Res Opin. 2018 Oct 6:1-21. doi: 10.1080/03007995.2018.1533457. [Epub ahead of print]

PMID:
30293449
6.

Rules to activate CD8+T cells through regulating subunits of opioid receptors by methionine enkephalin (MENK).

Jiao X, Wang X, Wang R, Geng J, Liu N, Chen H, Griffin N, Shan F.

Int Immunopharmacol. 2018 Oct 2;65:76-83. doi: 10.1016/j.intimp.2018.09.040. [Epub ahead of print]

PMID:
30290369
7.

The effect of naltrexone as a carboplatin chemotherapy-associated drug on the immune response, quality of life and survival of dogs with mammary carcinoma.

Machado MC, da Costa-Neto JM, Portela RD, D'Assis MJMH, Martins-Filho OA, Barrouin-Melo SM, Borges NF, Silva FL, Estrela-Lima A.

PLoS One. 2018 Oct 4;13(10):e0204830. doi: 10.1371/journal.pone.0204830. eCollection 2018.

8.

Synthesis, Biological Evaluation, and SAR Studies of 14β-phenylacetyl Substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and Opioid Receptor Profile.

Kumar V, Polgar WE, Cami-Kobeci G, Thomas MP, Khroyan TV, Toll L, Husbands SM.

Front Psychiatry. 2018 Sep 19;9:430. doi: 10.3389/fpsyt.2018.00430. eCollection 2018.

9.

Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects.

Saiz-Rodríguez M, Ochoa D, Herrador C, Belmonte C, Román M, Alday E, Koller D, Zubiaur P, Mejía G, Hernández-Martínez M, Abad-Santos F.

Basic Clin Pharmacol Toxicol. 2018 Oct 3. doi: 10.1111/bcpt.13141. [Epub ahead of print]

PMID:
30281924
10.

A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder.

Kohno M, Dennis LE, McCready H, Schwartz DL, Hoffman WF, Korthuis PT.

Drug Alcohol Depend. 2018 Sep 21;192:186-192. doi: 10.1016/j.drugalcdep.2018.07.045. [Epub ahead of print]

PMID:
30266003
11.

Therapeutic Drug Monitoring of Naltrexone and 6β-Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges.

Brünen S, Bekier NK, Hiemke C, Korf F, Wiedemann K, Jahn H, Kiefer F.

Alcohol Alcohol. 2018 Sep 27. doi: 10.1093/alcalc/agy067. [Epub ahead of print]

PMID:
30260366
12.

The Cholinergic System as a Treatment Target for Opioid Use Disorder.

Jensen KP, DeVito EE, Yip S, Carroll KM, Sofuoglu M.

CNS Drugs. 2018 Sep 26. doi: 10.1007/s40263-018-0572-y. [Epub ahead of print]

PMID:
30259415
13.

Acceptability of pharmacotherapy for hazardous alcohol use among men who have sex with men: Findings from a qualitative study.

Hsiang E, Jennings D, Matheson T, Hern J, Euren J, Santos GM.

Addict Behav Rep. 2018 Sep 18;8:122-127. doi: 10.1016/j.abrep.2018.09.004. eCollection 2018 Dec.

14.

Broccoli sprouts produce abdominal antinociception but not spasmolytic effects like its bioactive metabolite sulforaphane.

Guadarrama-Enríquez O, González-Trujano ME, Ventura-Martínez R, Rodríguez R, Ángeles-López GE, Reyes-Chilpa R, Baenas N, Moreno DA.

Biomed Pharmacother. 2018 Nov;107:1770-1778. doi: 10.1016/j.biopha.2018.09.010. Epub 2018 Sep 11.

PMID:
30257396
15.

Risk of hospitalisation and death related to baclofen for alcohol use disorders: Comparison with nalmefene, acamprosate, and naltrexone in a cohort study of 165 334 patients between 2009 and 2015 in France.

Chaignot C, Zureik M, Rey G, Dray-Spira R, Coste J, Weill A.

Pharmacoepidemiol Drug Saf. 2018 Sep 25. doi: 10.1002/pds.4635. [Epub ahead of print]

PMID:
30251424
16.

Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.

Toljan K, Vrooman B.

Med Sci (Basel). 2018 Sep 21;6(4). pii: E82. doi: 10.3390/medsci6040082. Review.

17.

Successful treatment of dermatomyositis with low-dose naltrexone.

Tran T, Chen A, Worswick S.

Dermatol Ther. 2018 Sep 24:e12720. doi: 10.1111/dth.12720. [Epub ahead of print] No abstract available.

PMID:
30246915
18.

Expression of β-endorphin in peripheral tissues after systemic administration of lipopolysaccharide as a model of endotoxic shock in mice.

Kido K, Shindo Y, Toda S, Masaki E.

Ann Endocrinol (Paris). 2018 Sep 19. pii: S0003-4266(18)30095-7. doi: 10.1016/j.ando.2018.06.001. [Epub ahead of print]

PMID:
30243475
19.

The use of naltrexone in pathological and problem gambling: A UK case series.

Ward S, Smith N, Bowden-Jones H.

J Behav Addict. 2018 Sep 1;7(3):827-833. doi: 10.1556/2006.7.2018.89. Epub 2018 Sep 21.

PMID:
30238780
20.

Treatment of psoriasis vulgaris using low-dose naltrexone.

Bridgman AC, Kirchhof MG.

JAAD Case Rep. 2018 Sep 18;4(8):827-829. doi: 10.1016/j.jdcr.2018.06.001. eCollection 2018 Sep. No abstract available.

Supplemental Content

Loading ...
Support Center